CD8A and neoplasm: showed that ENI to a dose of 8 Gy × 3 could disrupt the local and systemic anti-tumor response following combined primary head and neck tumor radiation (3 × 8 Gy) and immunotherapy (anti-CD25) mainly through a decrease in tumor antigen-specific T-cell priming in TDLNs and consequently decrease in circulating antigen-specific T cells (both CD4+ and CD8+) and infiltration into the tumor microenvironment (18).